BBIO
BridgeBio Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$76.82
+3.77%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 945.5M | 502.1M | 221.9M | 9.3M | 77.6M |
| Cost of Revenue | 61.3M | 28.3M | 3.9M | 2.4M | 3.4M |
| Gross Profit | 884.2M | 473.8M | 218.0M | 6.9M | 74.2M |
| Operating Expenses | |||||
| R&D Expense | 561.6M | 477.5M | 506.5M | 455.7M | 399.5M |
| SG&A Expense | 733.0M | 555.1M | 288.9M | 150.6M | 143.2M |
| General & Admin Expense | 200.9M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (486.0K) | 10.2M | 15.6M | 7.9M | 43.8M |
| Total Operating Expenses | 1.3B | 1.0B | 811.0M | 614.2M | 586.4M |
| Cost and Expenses | 1.4B | 1.1B | 814.9M | 616.7M | 589.9M |
| Operating Income (EBIT) | (409.9M) | (569.1M) | (593.0M) | (607.4M) | (512.2M) |
| Non-Operating | |||||
| Interest Income | 30.3M | 19.9M | 17.2M | 18.0M | 7.5M |
| Interest Expense | 133.6M | 53.1M | 99.3M | 81.3M | 80.4M |
| Net Interest Income | (103.3M) | (33.2M) | (82.0M) | (63.3M) | (72.9M) |
| Other Non-Op Income/Expense | (169.0M) | (165.9M) | 50.8M | (45.9M) | 27.6M |
| Non-Operating Income (excl Interest) | 35.4M | 112.8M | (150.1M) | (35.4M) | (108.0M) |
| EBT (Pre-Tax Income) | (579.0M) | (735.0M) | (542.2M) | (653.3M) | (484.7M) |
| Income Tax Expense | 1.2M | 555.0K | 1.2M | — | — |
| Bottom Line | |||||
| Net Income | (570.2M) | (729.3M) | (535.8M) | (643.2M) | (481.2M) |
| Earnings from Cont. Ops | (580.2M) | (735.5M) | (543.3M) | (653.3M) | (484.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (596.5M) | (729.3M) | (535.8M) | (643.2M) | (481.2M) |
| Per Share | |||||
| Basic EPS | ($3.04) | ($3.79) | ($2.88) | ($3.95) | ($3.35) |
| Diluted EPS | ($3.04) | ($3.79) | ($2.88) | ($3.95) | ($3.35) |
| Revenue Per Share | $4.82 | $2.55 | $1.19 | $0.06 | $0.53 |
| Shares | |||||
| Basic Shares Outstanding | 196.0M | 197.2M | 186.1M | 162.8M | 147.5M |
| Diluted Shares Outstanding | 196.0M | 197.2M | 186.1M | 162.8M | 147.5M |
| Profitability Metrics | |||||
| EBITDA | (440.6M) | (676.4M) | (436.8M) | (565.5M) | (397.4M) |
| D&A | 4.7M | 5.4M | 6.1M | 6.5M | 6.8M |
| EBIT | (445.3M) | (681.9M) | (442.9M) | (572.0M) | (404.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026